Search Results

Rituximab mono/combo therapies show promise for severe rheumatoid arthritis.

Subjects: RITUXIMAB; RHEUMATOID arthritis; RHEUMATOID arthritis treatment

• Source: Formulary. Feb2004, Vol. 39 Issue 2, p74-75. 2p.

Record details

Rituximab offers early promise in the treatment of RRMS.

Subjects: RITUXIMAB; MULTIPLE sclerosis; THERAPEUTICS

• Source: Formulary. Jul2007, Vol. 42 Issue 7, p446-446. 1/2p.

Record details

Labeling for the non-Hodgkin's lymphoma therapy rituximab.

• Source: Formulary. 2001, Vol. 36, Issue 7, pages. 482

Record details

FDA approved rituximab (Rituxan, Genentech/ Biogen Idec) in combination with anthracycline-based chemotherapy regimens.

• Source: Formulary. 2006, Vol. 41, Issue 3, pages. 111

Record details

The labeling for rituximab (Rituxan, Biogen Idec/Genentech) was revised to include a warning regarding reports of Hepatitis B virus (HBV).

• Source: Formulary. 2004, Vol. 39, Issue 11, pages. 524

Record details

Rituximab mono/combo therapies show promise for severe rheumatoid arthritis.

• Source: Formulary. 2004, Vol. 39, Issue 2, pages. 74

Record details

Rituximab offers early promise in the treatment of RRMS.

• Source: Formulary. 2007, Vol. 42, Issue 7, pages. 1

Record details

FDA has requested that a boxed warning be added to the prescribing information for rituximab (Rituxan, Genentech).

• Source: Formulary. 2007, Vol. 42, Issue 4, pages. 2

Record details

FDA actions in brief.

Subjects: DRUG approval; RITUXIMAB; UNITED States. Food & Drug AdministrationUNITED States

• Source: Formulary. Nov2006, Vol. 41 Issue 11, p557-557. 1/4p.

Record details

Rituximab IV infusion.

• Source: Formulary. 2010, Vol. 45, Issue 2, pages. 1

Record details